Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

EMA accepts Mereo's BPS-804 for Adaptive Pathways program

Feb. 20, 2017

Phase I/II results of rAAV2/5-hNA-GLU in children with MPS IIIB presented

Feb. 17, 2017

Clinical results with velmanase alfa in adults and children reported

Feb. 17, 2017

Clinical data reported for Fabry's disease candidate lucerastat

Feb. 16, 2017

Promising phase III results of UX-003 in patients with MPS VII

Feb. 16, 2017

Parsabiv launched in Japan

Feb. 16, 2017

Viking Therapeutics reaches funding agreement for clinical development of VK-2809

Feb. 16, 2017

AMAG Pharmaceuticals and Endoceutics sign U.S. license agreement for Intrarosa

Feb. 15, 2017

Aeterna Zentaris plans to pursue FDA registration of Macrilen following review of phase III data

Feb. 14, 2017

Viking Therapeutics reports results on VK-2809 in model of GSD Ia

Feb. 10, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026